Surmodics Total Assets 2006-2018 | SRDX

Surmodics total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
Surmodics Annual Total Assets
(Millions of US $)
2018 $164
2017 $137
2016 $133
2015 $99
2014 $105
2013 $102
2012 $104
2011 $157
2010 $170
2009 $186
2008 $191
2007 $171
2006 $157
2005 $124
Surmodics Quarterly Total Assets
(Millions of US $)
Q1 2018 $151
Q4 2018 $164
Q3 2018 $160
Q2 2018 $163
Q1 2017 $135
Q4 2017 $137
Q3 2017 $132
Q2 2017 $131
Q1 2016 $129
Q4 2016 $133
Q3 2016 $127
Q2 2016 $122
Q1 2015 $112
Q4 2015 $99
Q3 2015 $96
Q2 2015 $91
Q1 2014 $87
Q4 2014 $105
Q3 2014 $101
Q2 2014 $96
Q1 2013 $95
Q4 2013 $102
Q3 2013 $104
Q2 2013 $108
Q1 2012 $108
Q4 2012 $104
Q3 2012 $158
Q2 2012 $154
Q1 2011 $152
Q4 2011 $157
Q3 2011 $173
Q2 2011 $172
Q1 2010 $172
Q4 2010 $170
Q3 2010 $191
Q2 2010 $191
Q1 2009 $191
Q4 2009 $186
Q3 2009 $182
Q2 2009 $182
Q1 2008 $180
Q4 2008 $191
Q3 2008 $195
Q2 2008 $185
Q1 2007 $174
Q4 2007 $171
Q3 2007 $165
Q2 2007 $138
Q1 2006 $152
Q4 2006 $157
Q3 2006 $144
Q2 2006 $136
Q1 2005 $131
Q4 2005 $124
Q3 2005 $118
Q2 2005 $109
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.584B $0.081B
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $133.667B 26.06
Medtronic (MDT) Ireland $114.132B 16.69
Stryker (SYK) United States $69.756B 24.90
Boston Scientific (BSX) United States $49.905B 24.25
Baxter (BAX) United States $39.019B 25.03
Zimmer Biomet Holdings (ZBH) United States $25.114B 16.07
Smith & Nephew SNATS (SNN) United Kingdom $16.786B 0.00
Canopy Growth (CGC) Canada $16.315B 0.00
ResMed (RMD) United States $14.544B 27.58
Aurora Cannabis (ACB) Canada $9.179B 64.71
Bio-Rad Laboratories (BIO) United States $8.795B 50.45
Perrigo (PRGO) Ireland $6.734B 10.92
Hill-Rom Holdings (HRC) United States $6.397B 19.79
GW Pharmaceuticals (GWPH) United Kingdom $4.994B 0.00
Insulet (PODD) United States $4.964B 1664.20
ICU Medical (ICUI) United States $4.636B 28.71
Haemonetics (HAE) United States $4.354B 38.62
Hutchison China MediTech (HCM) China $3.962B 0.00
Agios Pharmaceuticals (AGIO) United States $3.443B 0.00
Neogen (NEOG) United States $3.004B 48.85
NuVasive (NUVA) United States $2.967B 25.77
Quidel (QDEL) United States $2.487B 22.25
National Vision Holdings (EYE) United States $2.276B 44.77
Aphria (APHA) $1.957B 0.00
HEXO (HEXO) $1.474B 0.00
Phibro Animal Health (PAHC) United States $1.338B 19.24
VAREX IMAGING (VREX) United States $1.234B 24.16
Cardiovascular Systems (CSII) United States $1.212B 870.25
AtriCure (ATRC) United States $1.076B 0.00
Lantheus Holdings (LNTH) United States $0.957B 25.86
Omeros (OMER) United States $0.929B 0.00
PetIQ (PETQ) United States $0.865B 24.76
Cerus (CERS) United States $0.831B 0.00
MacroGenics (MGNX) United States $0.820B 0.00
NanoString Technologies (NSTG) United States $0.781B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.725B 24.66
TG Therapeutics (TGTX) United States $0.717B 0.00
Evolus (EOLS) United States $0.708B 0.00
OraSure Technologies (OSUR) United States $0.589B 25.68
LeMaitre Vascular (LMAT) United States $0.555B 26.37
Meridian Bioscience (VIVO) United States $0.538B 16.02
Quanterix (QTRX) United States $0.515B 0.00
Insys Therapeutics (INSY) United States $0.332B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.329B 0.00
Utah Medical Products (UTMD) United States $0.326B 21.19
BioLife Solutions (BLFS) United States $0.302B 124.61
Vapotherm (VAPO) United States $0.287B 0.00
Rockwell Medical (RMTI) United States $0.270B 0.00
Cytosorbents (CTSO) United States $0.228B 0.00
Owens & Minor (OMI) United States $0.213B 2.91
Zynex (ZYXI) United States $0.172B 18.38
Bovie Medical (APYX) United States $0.140B 0.00
Chimerix (CMRX) United States $0.138B 0.00
Fonar (FONR) United States $0.128B 6.85
Chembio Diagnostics (CEMI) United States $0.122B 0.00
Surface Oncology (SURF) United States $0.114B 0.00
United-Guardian (UG) United States $0.089B 20.32
Female Health (VERU) United States $0.088B 0.00
InfuSystems Holdings (INFU) United States $0.085B 0.00
Neurotrope (NTRP) United States $0.075B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.069B 0.00
Trinity Biotech (TRIB) Ireland $0.067B 19.86
GUARDION HEALTH (GHSI) United States $0.054B 0.00
ImmuCell (ICCC) United States $0.045B 0.00
Senestech (SNES) United States $0.036B 0.00
Valeritas Holdings (VLRX) United States $0.031B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.024B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
Akers Biosciences Inc (AKER) United States $0.011B 0.00
NeuroMetrix (NURO) United States $0.007B 13.00